Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism

Drug Metabolism and Disposition

Volumn 33, Issue 1, 2005, Pages 139-146

  Picard, Nicolas ^a   Ratanasavanh, Damrong ^b   Prémaud, Aurélie ^a   Le Meur, Yonnick ^a   Marquet, Pierre ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCOSIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID ACYLGLUCURONIDE; MYCOPHENOLIC ACID PHENYL GLUCURONIDE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GLUCURONIDATION; HUMAN; HUMAN TISSUE; INTESTINE; INTESTINE MUCOSA; KIDNEY GRAFT; KIDNEY MICROSOME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; METABOLITE; MICHAELIS CONSTANT; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; URINALYSIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; MALE; MICROSOMES, LIVER; MYCOPHENOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 11144318750     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.001651     Document Type: Article

References (36)

1. Albert C, Vallée M, Beaudry G, Bélanger A, and Hum DW (1999) The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292-3302.
2. Antonio L, Xu J, Little JM, Burchell B, Magdalou J, and Radominska-Pandya A (2003) Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferase (UGT) and recombinant UGT1A6, UGT1A9 and UGT2B7. Arch Biochem Biophys 411:251-261.
3. Barbier O, Turgeon D, Girard C, Green MD, Tephly TR, Hum DW, and Bélanger A (2000) 3′-Azido-3′-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos 28:497-502.
4. Basu NK, Kole L, Kubota S, and Owens IS (2004) Human UDP- glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin. Drug Metab Dispos 32:768-773.
5. Bernard O and Guiliemette C (2004) The main role of UGT 1A9 in the hepatic metabolism of mycophenotic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778.
6. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
8. Bullingham R, Monroe S, Nicholls A, and Hale M (1996) Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single dose oral and intravenous administration. J Clin Pharmacol 36:315-324.
9. Bullingham R, Nicholls AJ, and Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455.
10. Cattaneo D, Perico N, Gaspari F, Gotti E, and Remuzzi G (2002) Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62:1060-1067.
11. Czernik PJ, Little JM, Barone GW, Raufman JP, and Radominska-Pandya A (2000) Glucuronidation of estrogens and retinoic acid and expression of UDP-glucuronosyltransferase 2B7 in human intestinal mucosa, Drug Metab Dispos 28:1210-1216.
12. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythimidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133.
13. Ebner T and Burchell B (1993) Substrates specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab Dispos 20:50-55.
14. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
15. Grams B, Harms A, Braun S, Strassburg CP, Manns PM, and Obermayer-Straub P (2000) Distribution and inducibility by 3-methylcholanthrene of family 1 UDP-glucuronosyltransferases in the rat gastrointestinal tract. Arch Biochem Biophys 377:255-265.
16. Hübner GI, Eismann R, and Sziegoleit W (1999) Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 21:536-539.
17. Mackenzie PI (2000) Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid, Ther Drug Monit 22:10-13.
18. McGurk KA, Brierley CH, and Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012.
19. Mojarrabi B and Mackenzie PI (1997) The human UDP glucuronosyltransferase UGT1A10 glucuronidates mycophenolic acid. Biochem Biophys Res Commun 238:775-778.
20. Morissette P, Albert C, Busque S, St-Louis G, and Vinet B (2001) In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit 23:520-525.
21. Parker G, Bullingham R, Kamm B, and Hale M (1996) Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 36:332-344.
22. Picard N, Cresteil T, Prémaud A, and Marquet P (2004) Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit, in press.
23. Pillot T, Ouzzine M, Fournel-Gigleux S, Lafaurie C, Radominska A, Burchell B, Siest G, and Magdalou J (1993) Glucuronidation of hyodeoxycholic acid in human liver: evidence for a selective role of UDP- glucuronosyltransferase 2B4. J Biol Chem 268:25636-25642.
24. Prémaud A, Rousseau A, Le Meur Y, Lachātre G, and Marquet P (2004) Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit, in press.
25. Ritter JK (2000) Roles of glucuronidation and UDP- glucuronosyltransferases in xenobiotic bioactivation reactions. Chem-Biol Interact 129:171-193.
26. Schütz E, Shipkova M, Armstrong VW, Wieland E, and Oellerich M (1999) Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 45:419-422.
27. Shipkova M, Armstrong VW, Oellerich M, and Wieland E (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25:1-16.
28. Shipkova M, Armstrong VW, Wieland E, Niedmann PD, Schütz E, Brenner-Weib G, Voihsel M, Braun F, and Oellerich M (1999) Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 126:1075-1081.
29. Shipkova M, Schütz E, Armstrong VW, Niedmann PD, Oellerich M, and Wieland E (2000) Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 46:365-372.
30. Shipkova M, Stassburg CP, Braun F, Steit F, Gröne H-J, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001a) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034.
31. Shipkova M, Wieland E, Schütz E, Wiese C, Niedmann PD, Oellerich M, and Armstrong VW (2001b) The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc 33:1080-1081.
32. Smak Gregoor PJ, van Gelder T, Hesse CJ, van Der Mast BJ, van Besouw NM, and Wiemar W (1999) Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 14:706-708.
33. Vietri M, Pietrabissa A, Mosca F, and Pacifici GM (2000) Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. Eur J Clin Pharmacol 56:659-664.
34. Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann PD, Armstrong VW, and Oellerich M (2000) Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 33:107-113.
35. Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, and Miller J (1997) Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy and analogous in vitro findings. Transplant Immunol 5:225-232.
36. Zucker K, Tsaroucha A, Olson L, Esquenasi V, Tzakis A, and Miller J (1999) Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 21:35-43.